top of page
The Professional Network for Healthcare Experts
Kelun’s Merck-Partnered ADC Delivers Phase III Win in First-Line PD-L1-Negative Lung Cancer
Sacituzumab tirumotecan plus Keytruda improves progression-free survival in advanced NSCLC, expanding potential role of ADC-immunotherapy combinations.
nuaxia
Jul 173 min read
AstraZeneca Acquires Global Rights to Dizal’s Zegfrovy in $1.5bn Lung Cancer Deal
The agreement expands AstraZeneca’s oncology portfolio with an oral EGFR inhibitor for non-small-cell lung cancer, as Dizal seeks to broaden Zegfrovy’s use into earlier lines of treatment.
nuaxia
Jul 153 min read
bottom of page